Related Experiment Videos
Iohexol cerebral angiography. Multicenter clinical trial.
Investigative Radiology
|January 1, 1985
Summary
New nonionic contrast media like iohexol significantly reduce patient discomfort during cerebral angiography compared to traditional ionic agents. This offers improved patient experience and potentially better outcomes, especially for sensitive cases.
Area of Science:
- Radiology
- Medical Imaging
- Pharmacology
Background:
- Ionic contrast media used in cerebral angiography often cause patient discomfort due to high osmolality.
- Hyperosmolality can lead to adverse physiological responses during imaging procedures.
Purpose of the Study:
- To compare the safety and efficacy of a new nonionic contrast agent, iohexol, against traditional ionic media (meglumine iothalamate and meglumine-Na diatrizoate) in cerebral angiography.
- To evaluate patient discomfort, physiological changes, and image quality associated with different contrast media.
Main Methods:
- A double-blind, multicenter trial involving 277 patients undergoing cerebral angiography.
- Evaluation of vital signs, cardiovascular and neurological status, and adverse reactions.
- Assessment of patient-reported discomfort and image visualization quality.
Main Results:
- Visualization quality was good or excellent across all tested contrast media.
- No significant physiological differences were noted between ionic and iohexol groups.
- Iohexol administration resulted in fewer patients experiencing large systolic blood pressure increases and significantly less patient discomfort compared to ionic media.
Conclusions:
- Iohexol, a nonionic contrast agent, offers a superior patient experience in cerebral angiography due to its low osmolality.
- Iohexol is particularly indicated for selective angiograms where patient comfort is critical and for patients with suspected blood-brain barrier disruption.